Effects of Exenatide Plus Rosiglitazone on β-Cell Function and Insulin Sensitivity in Subjects With Type 2 Diabetes on Metformin by DeFronzo, Ralph A. et al.
Effects of Exenatide Plus Rosiglitazone on
-Cell Function and Insulin Sensitivity in
Subjects With Type 2 Diabetes on
Metformin










LEONARD C. GLASS, MD
2
OBJECTIVE — Study the effects of exenatide (EXE) plus rosiglitazone (ROSI) on -cell
functionandinsulinsensitivityusinghyperglycemicandeuglycemicinsulinclamptechniquesin
participants with type 2 diabetes on metformin.
RESEARCH DESIGN AND METHODS — In this 20-week, randomized, open-label,
multicenterstudy,participants(meanage,5610years;weight,9316kg;A1C,7.80.7%)
continued their metformin regimen and received either EXE 10 g b.i.d. (n  45), ROSI 4 mg
b.i.d. (n  45), or EXE 10 g b.i.d.  ROSI 4 mg b.i.d. (n  47). Seventy-three participants
underwent clamp procedures to quantitate insulin secretion and insulin sensitivity.
RESULTS — A1C declined in all groups (P  0.05), but decreased most with EXEROSI
(EXEROSI, 1.3  0.1%; ROSI, 1.0  0.1%, EXE, 0.9  0.1%; EXEROSI vs. EXE or
ROSI,P0.05).ROSIresultedinweightgain,whileEXEandEXEROSIresultedinweightloss
(EXE,2.80.5kg;EXEROSI,1.20.5kg;ROSI,1.50.5kg;P0.05betweenand
within all groups). At week 20, 1st and 2nd phase insulin secretion was signiﬁcantly higher in
EXEandEXEROSIversusROSI(bothP0.05).Insulinsensitivity(Mvalue)wassigniﬁcantly
higher in EXEROSI versus EXE (P  0.014).
CONCLUSIONS — Therapy with EXEROSI offset the weight gain observed with ROSI
and elicited an additive effect on glycemic control with signiﬁcant improvements in -cell
function and insulin sensitivity.
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H
yperglycemia in type 2 diabetes is
caused by decreased insulin secre-
tion due to progressive -cell dys-
function, insulin resistance in peripheral
tissues, and increased hepatic glucose
output (1,2). Clinical questions focus on
treatment approaches that may address
these multiple defects and delay the pro-
gression of the disease. Although thiazo-
lidinediones (TZDs) have been shown to
improve -cell function (1–5), their pri-
mary effect is to decrease peripheral insu-
lin resistance (6–10), while biguanides
decrease hepatic glucose output (11). Ex-
enatide (EXE), a glucagon-like peptide-1
(GLP-1) receptor agonist, enhances glu-
cose-dependent insulin secretion and
suppresses elevated glucagon levels re-
sultinginadeclineinhepaticglucoseout-
put(12–15).Sincebiguanides,TZDs,and
GLP-1 agonists exert their effects on dif-
ferent pathophysiologic defects, it seems
reasonable to combine these agents in the
treatment strategy.
To improve our understanding of the
metabolic effects of combination therapy
targeted at pathophysiologic defects in
type 2 diabetes, we designed the present
study to quantitate insulin secretion and
insulin sensitivity when combining EXE
and rosiglitazone (ROSI) versus each
therapy alone in patients already on
metformin.
RESEARCH DESIGN AND
METHODS— Seventeen sites in the
U.S. recruited participants with type 2 di-
abetes from 2006 to 2008. Inclusion cri-
teria included age 18–75 years, BMI
25–40 kg/m
2, stable body weight for at
least 6 months prior to screening, A1C
6.8–10.0%, stable dose of metformin for
at least 6 weeks prior to screening and no
treatment with any other antidiabetic
medication, and absence of islet cell auto-
antibodies. The study was approved at
each site by a local institutional review
board in accordance with the principles
described in the Declaration of Helsinki.
All participants gave informed written
consent before participation.
Experimental design
This was a 20-week, randomized, open-
label, comparator-controlled, three-arm,
multicenterstudy.Participantscontinued
their metformin regimen and were ran-
domizedandstratiﬁedbasedonstudysite
bycomputer-generatedrandomsequence
to one of three treatment groups: 1) EXE
injection 5 g b.i.d. for the ﬁrst month
andthen10gb.i.d.thereafter;2)ROSI2
mg b.i.d. for the ﬁrst month and then 4
mg b.i.d. thereafter; and 3) combination
of EXEROSI dosed as above. Efﬁcacy
measurementsincludedA1C,glucose,in-
sulin,C-peptide,lipids,andbodyweight.
Safety measurements included adverse
events, vital signs, hematology, and
chemistries. The study was powered to
detect a signiﬁcant difference in the pri-
mary and the secondary end points be-
tween the EXE ROSI and ROSI groups.
The primary end point of the study was
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the hyperglycemic clamp test for which a
sample size of 39 would provide 80%
power to detect a signiﬁcant difference of
0.6 in the log-transformed ratio of ASI-
iAUC at 20 weeks over baseline. The sec-
ondary end point was the glucose area
under the curve (AUC) from 15 to 180
min during the meal challenge. An addi-
tional 51 participants (N  90) who un-
derwent only meal challenges would
provide 80% power to detect a signiﬁcant
differenceof380mmol/lperminbetween
EXEROSI and ROSI. Eight of the 17
sitesrecruitedsubjectstoundergothehy-
perglycemic and hyperinsulinemic-
euglycemic clamp test in addition to the
meal tolerance test. Subjects recruited at
these clamp sites could participate only
by consenting to all procedures.
Standardized meal challenge
Participants underwent a standardized
meal challenge test after an overnight fast
at baseline and end point. The test con-
sistedofeightouncesofaliquidmealsup-
plement (240 kcal, four g fat, 40 g
carbohydrate, 10 g protein) (Boost, Mead
Johnson Nutritionals). Plasma glucose,
insulin, and C-peptide were measured at
15,0,15,30,60,90,120,150,and180
min.Atstudyend,ROSIand/orEXEwere
administered 15 min prior to meal
ingestion.
Hyperglycemic clamp
The hyperglycemic clamp was performed
at baseline and end point as described
previously (16). Medications were with-
heldthemorningoftheprocedure.Atend
point, participants administered study
medication 15 min prior to the clamp. At
time0,bodyweight-adjustedintravenous
(IV) bolus of 20% glucose was adminis-
tered over 10 min to raise the plasma glu-
cose concentration to 8.3 mmol/l (150
mg/dl) above baseline. A variable glucose
infusion was then adjusted to maintain
the targeted glucose level. At 80 min, an
IV bolus of 5 g arginine (dissolved in 50
ml) was given over 45 s, and the glucose
level was maintained at 8.3 mmol/l (150
mg/dl) above baseline for 30 min.
Hyperinsulinemic-euglycemic clamp
Participants returned within one week af-
ter the hyperglycemic clamp (16). Medi-
cations were withheld the morning of the
procedure. Insulin was given as an IV bo-
lus(0.1units	kgbodyweight	desired
plasma insulin concentration of 100
mU/l) over 10 min followed by a contin-
uous infusion at 80 mU/min per m
2 for
120 min. Plasma glucose concentration
was maintained at 5 mmol/l by a variable
infusion of 20% glucose.
Statistical analyses
TheabsoluteandincrementalAUCs(iAUC)
for glucose, insulin, and C-peptide concen-
trations during the meal challenge and hy-
perglycemicclampwerecalculatedbythe
trapezoid method. For the meal test, the
insulinogenic index (I/G) was calculated
bytheinsulinAUCdividedbytheglucose
AUC, the Matsuda whole-body insulin
sensitivity index, and the disposition in-
dex (I/G 	 Matsuda was calculated as de-
scribed by Matsuda and DeFronzo [17]).
The M value, measured by insulin-
stimulated glucose disposal during the
euglycemic clamp, was used to quantify
whole-body insulin sensitivity (16). The
insulin secretion/insulin resistance (dis-
position) index from the clamp tests was
calculated by the insulin iAUC multiplied
byM/I,where“M”istheMvalue,“I”isthe
steady-state plasma insulin concentration
during the euglycemic clamp, and iAUC
is the incremental area under the curve
(17).
Statistical analyses were performed
by SAS Drug Development (SAS, Cary,
NC).Testswereperformedwith
0.05
without adjustment for multiplicities.
Unless speciﬁed otherwise, all analyses
were performed based on the intent-to-
treat principle and included participants
with a baseline and at least one postbase-
line value. The least squares mean (LS
mean)SEisreportedforallcontinuous
variables except for baseline characteris-
tics where mean  SD is reported. Fisher
exacttestwasusedtocomparecategorical
variables. An ANCOVA model with treat-
ment group as a factor and baseline value
of the dependent variable as a covariate
was used to compare continuous vari-
ables without repeated measurements af-
ter randomization. A mixed model
repeated-measures approach was used to




One hundred and thirty-seven partici-
pantswererandomizedandreceivedEXE
(45 randomized, 33 completed),
EXEROSI (47 randomized, 34 com-
pleted), ROSI (45 randomized, 34 com-
pleted). Seventy-three participants
participatedintheclampstudies(EXE,23
with seven withdrawals; EXEROSI, 24
with six withdrawals; ROSI, 23 with
seven withdrawals) (supplemental Fig. 1,
available in an online appendix at http://
care.diabetesjournals.org/cgi/content/full/
dc09-1521/DC1). Four participants
withdrew before receiving study medica-
tion. For the entire population, baseline
characteristics were similar between the
three groups (mean  SD): A1C  7.8 
0.7%; age  56  10 years; BMI 
32.5  4.3 kg/m
2; diabetes duration 
4.73.7years;number(%)female67
(49%); Caucasian  84 (61%); His-
panic  32 (23%); African American 
16 (12%); others  5 (4%). Correspond-
ing values in the clamp subset were:
A1C  8.0  0.8%; age  52  9 years;
BMI  32.4  4.2 kg/m
2; diabetes dura-
tion  4.7  4.6 years; number (%) fe-
male27(54%);Caucasian19(38%);
Hispanic  21 (42%); African Ameri-
can  8 (16%); others  2 (4%).
Metabolic parameters
A1C decreased in all groups, but the dec-
rement in EXEROSI was signiﬁcantly
greater than with EXE or ROSI alone (Ta-
ble1).After20weeks,fastingplasmaglu-
cosewassigniﬁcantlyreducedtoasimilar
extent in all groups; fasting insulin de-
creased signiﬁcantly from baseline with
ROSI and EXEROSI (P  0.001) but
did not change with EXE (Table 1).
Weight increased signiﬁcantly in the
ROSIgroupanddecreasedsigniﬁcantlyin
the EXE and EXEROSI groups (EXE
and EXEROSI vs. ROSI, P  0.001)
(Table 1).
Total cholesterol increased signiﬁ-
cantly in ROSI and EXEROSI and did
not change signiﬁcantly in the EXE group
(Table 1). Fasting HDL cholesterol did
not change signiﬁcantly from baseline in
any group. Fasting LDL cholesterol in-
creased signiﬁcantly from baseline with
ROSI (P  0.001). At end point, ROSI
had signiﬁcantly greater fasting LDL than
EXE(P0.008).Fastingtriglyceridesde-
clined signiﬁcantly from baseline with
EXE, but the change was not signiﬁcantly
different from other groups (Table 1).
Standardized meal challenge
At 20 weeks, the AUC for glucose
(AUCG), insulin (AUCI), and C-peptide
(AUCCP) signiﬁcantly decreased for all
treatment groups during the meal chal-
lenge (Table 2) (Fig. 1). The AUCG was
lower in EXEROSI (P  0.004) and
tended to be lower with EXE (P  0.065)
versus ROSI. AUCI was reduced to a
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0.047), but this did not reach statistical
signiﬁcanceforAUCCP.TheI/Gincreased
from baseline by 0.82 IU-min/ml/
mmol-min/l in EXE (P  0.003), by 0.03
IU-min/ml/mmol-min/l in EXEROSI,
anddecreasedfrombaselineby0.53IU-
min/ml/mmol-min/l in ROSI, but these
changes were not statistically signiﬁcant
(P0.926and0.061forEXEROSIand
ROSI, respectively) (Table 2). The Mat-
sudawhole-bodyinsulinsensitivityindex
(17) during the meal challenge was similar
in all groups at baseline and increased sig-
niﬁcantly in all groups at end point (all P
0.05)(Table2).Atendpointtheincreasein
the Matsuda index was greater in
EXEROSI versus EXE (P0.015) (Table
2). The disposition index (I/G 	 Matsuda)
was signiﬁcantly improved in all groups,
buttherewerenosigniﬁcantdifferencesbe-
tween groups at end point (Table 2).
Insulin secretion, hyperglycemic
clamp
In the 50 participants who completed the
baseline and end point hyperglycemic
clamps(Fig.1),1stphase(0–10min)and
2nd phase (10–70 min) insulin iAUC
were increased from baseline with both
EXE and EXEROSI (both P  0.05) but
not with ROSI (Table 2) (Fig. 1), and the
increase in insulin iAUC tended to be
greater in EXE versus EXEROSI (P 
0.09).ASI-iAUC,ameasureof-cellsecre-
tory capacity, was signiﬁcantly increased
withEXE(Table2).At20weeks,ASI-iAUC
was signiﬁcantly higher with EXE versus
EXEROSI and ROSI (both P  0.05). C-
peptide iAUC results paralleled the insulin
iAUC results (data not shown).
Insulin sensitivity, euglycemic
insulin clamp
Forty-seven participants completed both
baselineandendpointeuglycemicinsulin
clamps. EXEROSI and ROSI signiﬁ-
cantly improved the M value at 20 weeks
(P  0.05), while EXE had no signiﬁcant
effect on insulin-stimulated glucose dis-
posal. When M was adjusted for the
steady-state plasma insulin concentration
during the clamp (M/I), similar results
were observed (Fig. 2).
-Cell function
The disposition index, derived from the
hyperglycemic and euglycemic insulin
clamps, provides the gold standard mea-
Table 1—Metabolic parameters
LS Mean  SEM P
EXE EXEROSI ROSI
EXE vs.
EXEROSI EXE vs. ROSI
EXEROSI
vs. ROSI
n 45 47 45
HbA1C (%)
Baseline 7.8  0.1 7.8  0.1 7.9  0.1
20 weeks 7.0  0.1* 6.6  0.1* 6.9  0.1*
Change 0.9  0.1 1.3  0.1 1.0  0.1 0.016 0.720 0.039
Weight (kg)
Baseline 93.0  2.4 93.8  2.4 91.8  2.4
20 weeks 89.7  0.5* 91.3  0.5* 94.0  0.5*
Change 2.8  0.5 1.2  0.5 1.5  0.5 0.038 0.001 0.001
Fasting glucose (mmol/l)
Baseline 8.42  0.28 8.43  0.27 8.48  0.27
20 weeks 6.98  0.25* 6.84  0.24* 6.63  0.25*
Change 1.46  0.25 1.60  0.24 1.80  0.25 0.693 0.331 0.555
Fasting insulin (IU/ml)
Baseline 17.9  2.0 13.8  2.0 16.2  2.0
20 weeks 16.3  1.2 10.2  1.2* 11.9  1.2*
Change 0.2  1.2 5.9  1.2 4.2  1.2 0.001 0.011 0.316
Total fasting cholesterol (mmol/l)
Baseline 4.42  0.15 4.41  0.14 4.62  0.15
20 weeks 4.33  0.12 4.71  0.11* 4.89  0.12*
Change 0.13  0.12 0.26  0.11 0.44  0.12 0.020 0.001 0.276
Fasting HDL (mmol/l)
Baseline 1.13  0.05 1.17  0.05 1.17  0.05
20 weeks 1.16  0.03 1.19  0.03 1.20  0.03
Change 0.02  0.03 0.05  0.03 0.06  0.03 0.566 0.445 0.840
Fasting LDL (mmol/l)
Baseline 2.59  0.13 2.57  0.13 2.71  0.13
20 weeks 2.55  0.10 2.69  0.10 2.93  0.10*
Change 0.05  0.10 0.10  0.10 0.33  0.10 0.308 0.008 0.096
Fasting triglycerides (mmol/l)
Baseline 1.77  0.19 1.82  0.18 2.14  0.18
20 weeks 1.59  0.17* 1.94  0.16 2.01  0.17
Change 0.34  0.17 0.00  0.16 0.07  0.17 0.140 0.079 0.752
*P  0.05 from baseline.
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tion index from 80–90 min of the
hyperglycemic clamp increased signiﬁ-
cantly and similarly with EXE and
EXEROSI (both P  0.001) but not
with ROSI (Fig. 2). The disposition index
from 0–70 min during the hyperglycemic
clamp increased with EXE and EXEROSI
(both P  0.001) but not with ROSI.
Safety
The most common adverse events were
nausea (EXE 47; EXEROSI 47; ROSI
4%), vomiting (EXE 22; EXEROSI 19;
ROSI 0%), and diarrhea (EXE 7;
EXEROSI 21; ROSI 4%). Two partici-
pants in EXE discontinued due to nausea;
two in EXEROSI discontinued due to
nausea,oneduetovomiting,andonedue
to breast cancer; and one participant in
ROSI discontinued due to peripheral
Table 2—Meal challenge and hyperglycemic clamp results
LS Mean  SEM P
EXE EXEROSI ROSI








n 33 34 34
Glucose AUC (mmol-min/l)
Baseline 1,783  60 1,800  60 1,742  60
End point 1,215  51* 1,140  50* 1,349  51*
Change 560  51 635  50 426  51 0.296 0.065 0.004
Insulin AUC (IU-min/ml)
Baseline 6,116  723 5,203  712 6,797  734
End point 5,024  339* 4,152  336* 4,050  346*
Change 999  339 1,871  336 1,973  346 0.071 0.047 0.833
C-peptide AUC (nmol-min/l)
Baseline 333  18 330  18 342  18
End point 310  13 277  13* 282  13*
Change 24  13 58  13 53  13 0.067 0.118 0.805
I/G Index (AUC)
(IU-min/ml)/(mmol-min/l)
Baseline 3.64  0.48 3.05  0.47 4.10  0.48
20 weeks 4.41  0.27* 3.61  0.27 3.06  0.28
Change 0.82  0.27 0.03  0.27 0.53  0.28 0.041 0.001 0.160
Matsuda index
Baseline 4.0  0.6 4.4  0.6 3.4  0.6
20 weeks 5.6  0.8* 8.4  0.8* 7.1  0.8*
Change 1.6  0.8 4.4  0.8 3.1  0.8 0.015 0.205 0.258
I/G (AUC) 	 Matsuda
Baseline 10.8  1.0 8.8  1.0 10.9  1.0
20 weeks 17.1  1.4* 20.4  1.4* 18.4  1.5*
Change 7.0  1.4 10.3  1.4 8.2  1.5 0.111 0.550 0.325
Hyperglycemic Clamp (IU-min/ml)
n 16 18 16
ASI-iAUC
Baseline 643  107 686  104 786  114
20 weeks 1,449  187* 896  182 602  200
Change 747  187 195  182 100  200 0.039 0.004 0.282
1st phase iAUC (0–10 min)
Baseline 6  14 10  14 23  15
20 weeks 105  24* 59  24* 17  26
Change 99  24 54  25 12  26 0.195 0.018 0.252
2nd phase iAUC (10–70 min)
Baseline 937  291 740  282 1,125  309
20 weeks 5,436  833* 3,422  813* 487  891
Change 4,513  833 2,500  813 435  891 0.09 0.001 0.019
1st and 2nd phase iAUC (0–70 min)
Baseline 955  306 742  297 1,162  326
20 weeks 5,611  862* 3,527  842* 503  922
Change 4,671  862 2,587  842 437  922 0.09 0.001 0.02
Data are LS means  SEM. *P 0.05 from baseline. Matsuda Index 
10,000
FPG  FPI  G  1
, where FPG and FPI  fasting plasma glucose and insulin and
G  average glucose during the meal challenge.
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(47%) of ROSI participants versus eight
(18%) treated with EXE (P0.007). Four-
teen participants (30%) in EXEROSI de-
veloped pedal edema (not signiﬁcant vs.
EXEandvs.ROSI).Theoccurrenceofhy-
poglycemia (deﬁned as signs or symp-
toms associated with hypoglycemia and
with a glucose meter reading of 3.0
mmol/l) was not signiﬁcantly different
among EXE (n  2), EXEROSI (n  2),
andROSI(n0).Oneparticipanttreated
with EXEROSI reported severe hypo-
glycemia, deﬁned as requiring the assis-
tance of another person and associated
with a glucose meter reading of 2.84
mmol/l.
CONCLUSIONS — Abnormalities in
both insulin action and insulin secretion
occurearlyinthepathogenesisofdiabetes
(1,2,18–24).Therefore,treatmentoftype
2 diabetes should be initiated early and
target these pathogenic mechanisms in
order to improve -cell function and
ameliorate the underlying insulin
resistance.
This is the ﬁrst study to examine the
metabolic effects of combined TZD
(ROSI) and GLP-1 (EXE) therapy in inad-
equately controlled (mean A1C  7.8 
0.7%) metformin-treated patients. Limi-
tations include the open label design and,
despite randomization, a slightly lower
baseline M value in the EXEROSI
group. As per study design, study medi-
cationsweregivenpriortotheprocedures
and although this prevented discrimina-
tionbetweentheacuteandchroniceffects
of these therapies, the primary aim was to
studytheeffectsofthesetherapiesasused
in general practice.
The incidence of gastrointestinal side
effects was higher in subjects treated with
ESE and pedal edema was more common
in those on ROSI. While the overall per-
centage of subjects withdrawing from the
study due to adverse events was higher in
the EXEROSI group, there were no sta-
tistically signiﬁcant differences between
treatments in withdrawal rates due to ad-
verseevents(EXE,two[4%];EXEROSI,
ﬁve [11%]; ROSI, one [2%], P 
 0.05
between all groups).
The study employs the gold standard
measurements of insulin resistance (eugly-
cemic insulin clamp) and -cell function
(dispositionindex)anddemonstratesthat
EXE has a major effect to improve -cell
functionbutdoesnotexertanysigniﬁcant
insulin–sensitizing action as determined
by the M value during the insulin clamp.
Consistent with recently published re-
sults (25), EXE treatment markedly im-
proved both 1st and 2nd phase insulin
secretion (Table 2) (Fig. 1); glucose-
potentiated, arginine-stimulated insulin
secretion increased more than twofold
following EXE therapy. The disposition
Figure1—Glucoseandinsulinconcentrationsduringthemealchallengetestandinsulinconcentrationsduringthehyperglycemicclampbefore(f,
broken line) and after (E, solid line) treatment with EXE, EXEROSI, or ROSI. Arrows indicate time of arginine stimulation (ARG) during the
hyperglycemic clamp. Data are presented as LS means  SE for the meal challenge test and LS means for the hyperglycemic clamp.
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(0–10, 10–70, and response to arginine
stimulation) also increased dramatically.
These favorable effects of EXE on -cell
function also were observed during the
meal tolerance test (I/G 	 Matsuda in-
dex),demonstratingthephysiologicrel-
evance of the observations. Further,
EXE signiﬁcantly reduced weight, A1C




by different mechanisms. TZD caused a
twofold increase in insulin sensitivity,
measured as M/I during the euglycemic
insulin clamp or the Matsuda index dur-
ing the meal tolerance test. The improve-
ment in insulin sensitivity was associated
with the signiﬁcant reduction in the insu-
lin response during the meal tolerance
test. Despite the reductions in insulin re-
sponse, the disposition index during the
meal tolerance test increased signiﬁcantly
(Table 2). Thus, in addition to its insulin
sensitizing effect, ROSI also improved
-cell function despite modest weight
gain, which was consistent with previ-
ously published results (9).
In metformin-treated patients, com-
bination EXE-ROSI therapy reduced A1C
(‚  1.3%) to a greater extent than ei-
ther EXE alone (‚  0.9%) or ROSI
alone (‚  1.0%). This greater reduc-
tion in A1C primarily was accounted for
by a greater reduction in postprandial
plasma glucose excursion after the meal
(Table2)withasimilardecrementinfast-
ing plasma glucose (Table 1). The beneﬁ-
cial effect of EXEROSI on A1C was due
totwofactors1)asigniﬁcantlygreaterim-
provement in insulin sensitivity (M/I dur-
ing the insulin clamp) (Fig. 2) and 2)a
signiﬁcant improvement in -cell func-
tionasmeasuredbythedispositionindex.
Although the amount of insulin secreted
in response to glucose alone or with argi-
nineduringthehyperglycemicclampwas
Figure 2—Disposition index, M value, and M/I index before ( ) and after (f) treatment with EXE, EXEROSI, and ROSI. *P  0.05 when
compared with baseline, †P  0.05 between EXEROSI and ROSI at baseline. Data are LS means  SE. BL, baseline; E, exenatide; ER, exenatide
plus rosiglitazone; EP, end point; I, steady-state plasma insulin concentration during the euglycemic clamp; M, insulin-stimulated glucose disposal
during the euglycemic clamp; R, rosiglitazone.
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combinationtherapycomparedwithEXE
alone, the disposition index of -cell
function was similar in the EXE and
EXEROSI groups. This indicates that
combinationtherapyimprovesinsulinse-
cretion as a function of insulin sensitivity.
These improvements in glucose metabo-
lism were accompanied by a decrease in
weight in contrast to the weight gain ob-
served with ROSI alone.
Although studies of longer duration
and with a larger number of subjects will
be necessary to examine the long-term ef-
fects of combination therapy with EXE
plus a TZD in type 2 diabetic patients in-
adequately controlled on metformin, the
presentresultsindicatethatthiscombina-
tion improves both insulin resistance and
the defect in insulin secretion.
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